Synopsis
Choose, initiate and monitor long-acting injectable antipsychotics through shared decision making, match oral tolerability and product-specific loading or overlap requirements, prevent missed-dose errors, and preserve dignity, consent and physical-health surveillance.
- Offer a long-acting injectable when the person prefers it after an acute episode or when avoiding covert non-adherence is a clinical priority within the care plan.
- Do not present injections as punishment or proof of reliability; compare convenience, privacy, reversibility, injection discomfort and prolonged adverse effects openly.
- Establish oral response and tolerability when the product requires it, then follow the exact SmPC initiation, overlap, site, needle, interval and missed-dose instructions.
- Different preparations are not dose-equivalent: aripiprazole monthly requires a defined oral or two-injection start, while paliperidone deltoid loading doses change in mild renal impairment and it is not recommended below creatinine clearance 50 mL/min.
- Confirm identity, medicine, formulation, dose, last administration, due date, allergies, interactions, consent and physical state before every injection.
- A long-acting formulation improves exposure visibility but does not guarantee adherence to appointments, biological response or engagement with psychosocial care.
- Continue the same metabolic, cardiovascular, movement, prolactin and subjective adverse-effect monitoring required for the active antipsychotic.
- Use a product-specific missed-dose algorithm and specialist or pharmacy advice rather than simply giving the usual dose after a prolonged gap.
Key red flags
An injection given without confirming the exact product, last dose and missed-dose interval can cause underexposure, unintended loading or excessive accumulation.
Fever, rigidity, autonomic instability or altered consciousness after any dopamine-blocking depot raises neuroleptic malignant syndrome and requires urgent treatment.
Painful swelling, neurovascular change, severe bleeding or suspected intravascular administration requires immediate examination and escalation.
New pregnancy, major renal or hepatic change, a strong enzyme interaction or an agent-specific tobacco-smoking effect may invalidate a previously stable drug and dose plan.
Refusal, distress or withdrawal of consent during administration must pause the procedure unless a clearly documented lawful authority and proportionate plan applies.
Investigation priorities
Confirm oral response, tolerability, licence, organ function, interactions, physical baseline and preference.
Management branches
A long-acting formulation is being considered after response to acute treatment.
- Compare oral and injectable options, including benefit, adverse effects, reversibility, appointments, privacy, needle concerns and the person's previous experiences.
- Verify licence, oral tolerability, physical baseline, organ function, interactions and the exact initiation and missed-dose requirements.
- Document informed preference, administration site and schedule, follow-up owner and how psychological, social and physical care will continue.